CMV Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T Cell Therapy

Investigators prospectively enrolled 72 adult cytomegalovirus (CMV)-seropositive CD19-, CD20-, or BCMA-targeted chimeric antigen receptor-modified T cell immunotherapy (CARTx)-recipients and tested plasma for CMV pre- and weekly up to twelve weeks post-CARTx.